CompletedNot Applicable

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

United States72 participantsStarted 2022-07-15

Plain-language summary

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient is ≥18 years of age
✓. Written Informed Consent provided by patient
✓. Diagnosis of any kind of carcinoma
✓. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
✓. Proceeding onto therapy for treatment
✓. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

Exclusion criteria

✕. Lack of informed consent
✕. Unable to obtain sufficient sample

What they're measuring

BOR

Timeframe: 12 months

Trial details

NCT IDNCT05461430

SponsorTravera Inc

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-03-23

View on ClinicalTrials.gov More Pleural Effusion, Malignant trials